Pivotal Bio Venture Partners Investment Advisor LLC Vaxcyte, Inc. Transaction History
Pivotal Bio Venture Partners Investment Advisor LLC
- $106 Million
- Q2 2025
A detailed history of Pivotal Bio Venture Partners Investment Advisor LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Pivotal Bio Venture Partners Investment Advisor LLC holds 1,305,125 shares of PCVX stock, worth $55.7 Million. This represents 40.07% of its overall portfolio holdings.
Number of Shares
1,305,125
Previous 710,734
83.63%
Holding current value
$55.7 Million
Previous $26.8 Million
58.1%
% of portfolio
40.07%
Previous 37.54%
Shares
11 transactions
Others Institutions Holding PCVX
# of Institutions
324Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$627 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$512 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$510 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$424 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$256 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.53B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...